Fund shareholders of CG ONCOLOGY INC
ISIN US1569441009 · United States
- Fund shareholders
- 326
- Of which ETFs
- 60 266 other funds
- Value held
- ≈ 2.6B $ 2.5B $ · 19.8K € · 13.3M SEK
- Share of capital
- 41.0 % of 88.6M shares on Aug 5, 2026
326 funds hold this company. This table lists the 325 that declare it in a regulatory filing. 1 more fund publishes its holdings in its own report. The “Fund reports” tab lists it, with its weight.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| T. Rowe Price Innovation Leaders ETF T. Rowe Price Exchange-Traded Funds, Inc. | 366 | 26K $ | 0.14 % | 0.00 % | as of Jun 30, 2026 ↗ |
| MFS Global Alternative Strategy Fund MFS Series Trust XV | 342 | 24.3K $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
| WisdomTree BioRevolution Fund WisdomTree Trust | 340 | 24.2K $ | 0.90 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Fidelity Flex Small Cap Focused Index Fund Fidelity Salem Street Trust | 338 | 24.1K $ | 0.13 % | 0.00 % | as of Jul 31, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 303 | 21.5K $ | 0.11 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Fidelity Series Sustainable U.S. Market Fund Fidelity Summer Street Trust | 261 | 18.6K $ | 0.03 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Innovator U.S. Small Cap Managed 10 Buffer ETF Innovator ETFs Trust | 257 | 18.3K $ | 0.17 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Strategic Allocation: Conservative Fund American Century Strategic Asset Allocations Inc | 220 | 15.7K $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
| iShares Texas Equity ETF iShares Trust | 208 | 14.8K $ | 0.09 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Fidelity Enhanced Small Cap Growth ETF Fidelity Covington Trust | 208 | 14.8K $ | 0.26 % | 0.00 % | as of Jun 30, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 198 | 14.1K $ | 0.12 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 183 | 13K $ | 0.08 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Wilshire 5000 Index Fund Wilshire Mutual Funds Inc | 159 | 11.3K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| SIMT Multi-Asset Inflation Managed Fund SEI INSTITUTIONAL MANAGED TRUST | 143 | 10.2K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 109 | 7.7K $ | 0.11 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Avantis Inflation Focused Equity ETF American Century ETF Trust | 91 | 5.7K $ | 0.06 % | 0.00 % | as of May 31, 2026 ↗ |
| Founders 100 ETF Founder Funds Trust | 86 | 6.1K $ | 0.12 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 67 | 4.8K $ | 0.13 % | 0.00 % | as of Jun 30, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 62 | 4.4K $ | 0.05 % | 0.00 % | as of Jul 31, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 59 | 4.2K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 55 | 3.4K $ | 0.02 % | 0.00 % | as of May 31, 2026 ↗ |
| Goldman Sachs MSCI World Private Equity Return Tracker ETF Goldman Sachs ETF Trust | 26 | 1.6K $ | 0.01 % | 0.00 % | as of May 31, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 21 | 1.5K $ | 0.03 % | 0.00 % | as of Jun 30, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 18 | 1.1K $ | 0.10 % | 0.00 % | as of May 31, 2026 ↗ |
| A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. | 19.8K € | 0.54 % | as of Dec 31, 2025 ↗ |
Funds that publish their own holdings
| Fund | Weight in fund | |
|---|---|---|
| Pictet - Biotech Pictet Asset Management (Europe) S.A. | 2.00 % | as of Sep 30, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| ALPS Medical Breakthroughs ETF ALPS ETF TRUST | 3.35 % | as of May 31, 2026 ↗ |
| Tema Oncology ETF Tema ETF Trust | 2.43 % | as of May 31, 2026 ↗ |
| Pictet - Biotech Pictet Asset Management (Europe) S.A. | 2.00 % | as of Sep 30, 2025 ↗ |
| Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST | 1.46 % | as of Jun 30, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.20 % | as of Jun 30, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 1.17 % | as of Jun 30, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 1.08 % | as of Jul 31, 2026 ↗ |
| BIOTECHNOLOGY ULTRASECTOR PROFUND ProFunds | 1.03 % | as of Jul 31, 2026 ↗ |
| Meridian Small Cap Growth Fund Meridian Fund Inc | 1.02 % | as of Jun 30, 2026 ↗ |
| Lord Abbett Health Care Fund LORD ABBETT SECURITIES TRUST | 1.02 % | as of Jul 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 323 | +20 | 36,285,864 | +8.3 % |
| 2026Q2 | 303 | +44 | 33,492,521 | +14.9 % |
| 2026Q1 | 259 | +40 | 29,149,569 | +18.3 % |
| 2025Q4 | 219 | +21 | 24,635,869 | +8.0 % |
| 2025Q3 | 198 | +11 | 22,820,507 | +24.3 % |
| 2025Q2 | 187 | +21 | 18,361,596 | +13.2 % |
| 2025Q1 | 166 | +17 | 16,213,904 | +33.7 % |
| 2024Q4 | 149 | +5 | 12,122,737 | +64.5 % |
| 2024Q3 | 144 | +20 | 7,371,109 | +13.8 % |
| 2024Q2 | 124 | +114 | 6,474,994 | +414.8 % |
| 2024Q1 | 10 | 1,257,721 |
Institutional managers
227 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| RTW INVESTMENTS, LP | 6,984,808 | 472.7M $ | as of Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 6,720,389 | 454.8K $ | as of Mar 31, 2026 |
| Decheng Capital LLC | 6,371,669 | 431.2M $ | as of Mar 31, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 5,371,232 | 363.5M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 5,064,180 | 342.7M $ | as of Mar 31, 2026 |
| FMR LLC | 3,764,844 | 254.8M $ | as of Mar 31, 2026 |
| TCG Crossover Management, LLC | 3,670,206 | 248.4M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3,652,980 | 247.2K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 2,647,054 | 179.2M $ | as of Mar 31, 2026 |
| Foresite Capital Management VI LLC | 2,221,474 | 150.3M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,596,864 | 108.1M $ | as of Mar 31, 2026 |
| FRANKLIN RESOURCES INC | 1,507,005 | 102M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 1,449,364 | 98.1M $ | as of Mar 31, 2026 |
| DV Trading LLC | 1,439,393 | 97.4M $ | as of Mar 31, 2026 |
| UBS Group AG | 1,311,978 | 88.8M $ | as of Mar 31, 2026 |
| ALLIANCEBERNSTEIN L.P. | 1,290,087 | 53.6M $ | as of Mar 31, 2026 |
| Avidity Partners Management LP | 1,288,948 | 87.2M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,159,239 | 78.5M $ | as of Mar 31, 2026 |
| ACORN CAPITAL ADVISORS, LLC | 1,130,501 | 76.6M $ | as of Mar 31, 2026 |
| EcoR1 Capital, LLC | 1,102,000 | 74.6M $ | as of Mar 31, 2026 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,064,966 | 72.1M $ | as of Mar 31, 2026 |
| Foresite Capital Management V, LLC | 1,004,050 | 68M $ | as of Mar 31, 2026 |
| Driehaus Capital Management LLC | 999,623 | 67.7M $ | as of Mar 31, 2026 |
| BRAIDWELL LP | 984,783 | 66.7M $ | as of Mar 31, 2026 |
| ORBIMED ADVISORS LLC | 948,267 | 64.2M $ | as of Mar 31, 2026 |
Declared shareholders of CG ONCOLOGY INC
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| RTW Investments, LP and 1 other | 9.70 % | 8,514,590 | as of Jun 30, 2026 · SCHEDULE 13G |
| BlackRock, Inc. | 6.80 % | 6,023,696 | as of Jun 30, 2026 · SCHEDULE 13G |
| Wellington Management Group LLP and 3 others | 6.00 % | 5,324,751 | as of Jun 30, 2026 · SCHEDULE 13G |
| Foresite Capital Fund V, L.P. and 6 others | 4.90 % | 4,306,174 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of CG ONCOLOGY INC". https://titelia.com/en/stocks/cg-oncology-inc-US1569441009